These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11427259)

  • 1. Present anti-measles immunity in Jordan.
    Bdour S; Batayneh N
    Vaccine; 2001 Jul; 19(28-29):3865-9. PubMed ID: 11427259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
    Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
    [No Abstract]   [Full Text] [Related]  

  • 4. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mumps: immune status of adults and epidemiology as a necessary background for choice of vaccination strategy in Jordan.
    Batayneh N; Bdour S
    APMIS; 2002 Aug; 110(7-8):528-34. PubMed ID: 12390410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
    Christenson B; Böttiger M
    Vaccine; 1994 Feb; 12(2):129-33. PubMed ID: 8147093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J; Putz L; Schneider F
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
    Glikmann G; Petersen I; Mordhorst CH
    Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interruption of measles transmission in Gipuzkoa (Basque Country), Spain.
    Cilla G; Basterretxea M; Artieda J; Vicente D; Pérez-Trallero E
    Euro Surveill; 2004 May; 9(5):29-31. PubMed ID: 15208472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
    Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
    Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
    Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.